Poster discussion hub abstracts 33 (8.2%). Among fetuses with structural ultrasound abnormalities and normal karyotype(n=369) that underwent CMA, the detection rate of copy number variants (CNV) was 22.2% (82/369), including pathogenic CNV in 11.4% (42/369) and variants of uncertain clinical significance (VOUS) in 10.8% (40/369). In the groups of cardiac, central nervous, musculoskeletal, facial and urogenital malformations, the rate of the pathogenic CNV were 16.6% (38/229), 21.9% (14/64), 15.5% (15/97), 13.5% (7/52) and 18.8% (6/32) respectively. Ultrasound anomaly restricted to one anatomical system (n=238) had a 10.5% (n=25) chance of carrying a pathogenic CNV, while this chance increased to 13.0% (n=17) for multiple ultrasound anomalies (n=131). Conclusions: In the assessment of genetic abnormalities in pregnancies with fetal anomalies, the diagnostic yield may be increased by 22% if CMA is used as a complementary tool to conventional cytogenetics. Our results suggest that CMA is valuable in prenatal genetic diagnosis of fetuses with fetal anomalies.
Objectives: Circulating fetal cells from the maternal blood possess the potential to be applied as candidates in a non-invasive prenatal test (cbNIPT). Fetal cells have an advantage over cell free fetal DNA (cffDNA) in that the complete fetal genome is neither degraded nor it is contaminated with maternal DNA. Thus, it should be more accessible for chromosomal and subchromosomal analysis. We present a method for enriching fetal trophoblast cells from maternal blood, subsequent amplification of the fetal genome, and detection of chromosomal variations in the genome. Methods: Blood samples were collected in gestational week 10 to 13. Fetal trophoblast cells were enriched and stained using fetal cell specific antibodies. The enriched cell fraction was scanned, and for samples coming from high risk pregnancies, positively detected fetal cells were picked using a capillary based cell picking instrument. Subsequent whole genome amplification was performed on fetal cells and the DNA was analysed by array CGH. Results: From 190 pregnancies, an average of 12.8 (range 1-46) fetal trophoblast cells were recovered from 30 ml of maternal blood. From high risk pregnancy samples, fetal cells were picked and whole genome amplification was performed which resulted in DNA in quantity and quality high enough to generate array CGH profiles. We present a range of cases comparing our non-invasive cell based prenatal test results with CVS array CGH results. These includes aneuploidies, both full and mosaics, and sub-chromosomal cases, for e.g. an unbalanced translocation t(4;8) resulting in a 31 Mb deletion and a 30 Mb duplication, and a partial Trisomy 21 with a 12.4 Mb duplication of chromosome 21. Conclusions: Results from the genome analyses on fetal trophoblast cells enriched from maternal blood were verified by array CGH on CVS samples. Chromosomal and sub-chromosomal analyses can be performed on fetal cells enriched from maternal blood.
The developed method has the future potential of being offered as a cell-based NIPT with large genomic coverage. Objectives: Epigenetic mechanisms might play a role in Down's syndrome (DS), which is the most common aneuploidy in man.
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In our previous work, we studied miRNA expressions in normal and trisomic placentas. We have found seven miRNAs significantly upregulated in DS placentas. We would expect, according to biological functions of miRNA, that similar findings could be present in maternal plasma of affected pregnancies. Methods: A total of 26 plasma samples from pregnant women -13 bearing DS fetuses and 13 normal karyotype fetuses, were included. Genome-wide miRNA expressions were profiled using Affymetrix miRNA 4.1 array strips. Results were evaluated using Partek Genomics Suite. The one-way ANOVA with a cut-off p-value < 0.05 and Benjamini-Hochberg correction for multiple testing was used for detection of differentially expressed miRNAs.
Results:
We identified 61 human miRNAs as being significantly dysregulated between compared groups of samples. Unlike the placenta, most of these miRNAs (44) were down-regulated in plasma of women bearing the DS fetus. Many biological pathways were identified as being potentially influenced by altered miRNA levels. Cell communication and signalling pathways were between the most enriched ones. Seven miRNAs, previously determined as upregulated in DS placentas, did not differ on the plasma level. Conclusions: Our study shows that differences of miRNA profiles between normal and DS fetuses are detectable even on the level of maternal plasma. Such differences could mirror alterations in placental development and they deserve further study. 
